ReceptoPharm Finishes AMN Study

ReceptoPharm, a subsidiary of Nutra Pharma, has successfully completed the Phase IIb/IIIa clinical trial of its drug RPI-78M as a treatment for adrenomyeloneuropathy (AMN).

Similar to multiple sclerosis, AMN is a rare inherited metabolic disorder that affects approximately 30,000 people worldwide. Slowly progressive over several decades, it is characterized by the loss of the fatty covering on nerve fibers within the brain, thereby degenerating the adrenal gland.

ReceptoPharm said it expects to present the study’s findings by the end of next month. It has applied for orphan drug status in the U.S. and intends to do so in the EU.